Vildagliptin in the treatment of type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 12, 2011, Pages 1967-1973

  Stamataros, George ^a   Schneider, Stephen H ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

DPP 4 inhibitor; Oral antidiabetic agent; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; PLACEBO; VILDAGLIPTIN;

ANGIONEUROTIC EDEMA; BRONCHITIS; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HEADACHE; HUMAN; HYPOGLYCEMIA; INFLUENZA; LIVER DYSFUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

ADAMANTANE; ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; NITRILES; PYRROLIDINES;

EID: 79960448263     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.593508     Document Type: Review

References (49)

1. International Diabetes Federation. Diabetes Atlas 2009. 4th edition. Available from: www.diabetesatlas.org [Last accessed 1 February 2011]
2. AACE/ACE Consesus Statement on Type 2 Diabetes Mellitus 2009. Available from: www.aace.com [Last accessed 1 February 2011]
3. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12 (Pubitemid 29254858)
4. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
5. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249-58
6. Diabetes Control and Complications Trial (DCCT) Research Group. N Engl J Med 1993;329:977-86
7. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
8. National Committee for Quality Assurance. The state of health care quality 2010 report. Washington, DC: National Committee for Quality Assurance. Available from: http://web.ncqa.org [Last accessed 1 February 2011]
9. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65
10. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705 (Pubitemid 46048557)
11. Villhauer EB, Brinkman JA, Naderi GB, et al.1-[[(3-Hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89 (Pubitemid 36702545)
12. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2008;68:2387-409
13. He H, Tran P, Yin H, et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009;37:536-44
14. He Y, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007;46:577-88 (Pubitemid 47025358)
15. Novartis Pharmaceuticals UK Ltd. Galvus 50 mg tablets. Available from: www.emc.medicines.org.uk [Last accessed 1 February 2011]
16. He YL, Sabo R, Campestrini J, et al. The influence of hepatic impairment on the pharmacokinetics of dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Europ J Clinical Pharmacol 2007;63(12):677-86 (Pubitemid 46911348)
17. He YL, Sabo R, Campestrini J, et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 2007;65:338-46
18. He YL, Sabo R, Picard F, et al. Lack of pharmacokinetic interaction between vildagliptin and metformin in patients with type 2 diabetes [abstract PIII-16]. Clin Pharmacol Ther 2006;79:62
19. Serra DB, He YL, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction [abstract no. 2192-PO]. Diabetes 2005;54(Suppl 1):A528
20. Barilla D, He Y, Balez S, et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide [abstract no. 1967 PO]. Diabetes 2004;53(Suppl 2):A470
21. Novartis Pharmaceuticals UK Ltd. Eucreas 50 mg/850 mg tablets. Available from: www.emc.medicines.org.uk [Last accessed 1 February 2011]
22. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008;31:30-5
23. Azuma K, Radikova Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:459-64 (Pubitemid 351240816)
24. Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008;31:108-13
25. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92:1249-55 (Pubitemid 46556394)
26. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94 (Pubitemid 41159387)
27. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692-8 (Pubitemid 41601073)
28. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8 (Pubitemid 46240373)
29. Dejager S, Razac S, Foley J, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24 week double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-23 (Pubitemid 46580622)
30. Pratley R, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients. Diabetes Care 2007;30:3017-22
31. Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:1114-24
32. Schweizer A, Couturier A, Foley J, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007;24:955-61 (Pubitemid 47301637)
33. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11:804-12
34. Rosenstock J, Baron M, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 2007;30:217-23 (Pubitemid 46198322)
35. Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:571-8
36. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008;25:435-41 (Pubitemid 351490110)
37. Bosi E, Dotta F, Jia Y, et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:506-15
38. Ahren B, Gomis R, Standl E, et al. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80 (Pubitemid 39565052)
39. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5 (Pubitemid 46556583)
40. Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2010;89:216-23
41. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled on sulphonylurea. Diabetes Obes Metab 2008;10:1027-56
42. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-9
43. Bolli G, Dotta F, Minic B, et al. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009;11:589-95
44. Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled on metformin: results of the Galiant trial-a primary care, type 2 diabetes study. Diabetes Obes Metab 2009;11:978-86
45. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55 (Pubitemid 46701545)
46. FDA Postmarket Drug Safety. Available from: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm [Last accessed 1 February 2011]
47. Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels. Diabetes Care 2010;33:1859-64
48. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). U.K. Prospective Diabetes Study Group. Lancet 1998;352:837-53
49. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004;36:804-10 (Pubitemid 40115903)